Isthmus Partners LLC Raises Position in OmniAb, Inc. (NASDAQ:OABI)

Isthmus Partners LLC raised its holdings in shares of OmniAb, Inc. (NASDAQ:OABI) by 1.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 453,135 shares of the company’s stock after buying an additional 7,001 shares during the quarter. Isthmus Partners LLC owned about 0.32% of OmniAb worth $1,604,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in OABI. Murchinson Ltd. bought a new stake in shares of OmniAb during the 3rd quarter valued at about $4,230,000. Barclays PLC lifted its position in OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares during the last quarter. BBR Partners LLC lifted its position in OmniAb by 250.0% during the third quarter. BBR Partners LLC now owns 70,000 shares of the company’s stock valued at $296,000 after purchasing an additional 50,000 shares during the last quarter. Atria Investments Inc purchased a new position in OmniAb in the 3rd quarter worth approximately $148,000. Finally, State Street Corp increased its holdings in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after buying an additional 34,654 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors.

Insider Transactions at OmniAb

In related news, CFO Kurt A. Gustafson sold 15,526 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $50,304.24. Following the sale, the chief financial officer now directly owns 212,720 shares of the company’s stock, valued at $689,212.80. This trade represents a 6.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Charles S. Berkman sold 25,489 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $82,584.36. Following the transaction, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. This represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,260 shares of company stock worth $376,601. Insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Price Performance

Shares of OmniAb stock opened at $3.40 on Monday. OmniAb, Inc. has a one year low of $3.10 and a one year high of $5.72. The business’s 50 day simple moving average is $3.46 and its two-hundred day simple moving average is $3.85. The stock has a market capitalization of $480.13 million, a P/E ratio of -5.48 and a beta of -0.14.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.